Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies
- PMID: 39739162
- DOI: 10.1007/s12602-024-10431-z
Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies
Abstract
Various types of liver or hepatic diseases cause the death of about 2 million people worldwide every year, of which 1 million die from the complications of cirrhosis and another million from hepatocellular carcinoma and viral hepatitis. Currently, the second most common solid organ transplant is the liver, and the current rate represents less than 10% of global transplant requests. Hence, finding new approaches to treat and prevent liver diseases is essential. In liver diseases, the interaction between the liver, gut, and immune system is crucial, and probiotics positively affect the human microbiota. Probiotics are a non-toxic and biosafe alternative to synthetic chemical compounds. Health promotion by lowering cholesterol levels, stimulating host immunity, the natural gut microbiota, and other functions are some of the activities of probiotics, and their metabolites, including bacteriocins, can exert antimicrobial effects against a broad range of pathogenic bacteria. The present review discusses the available data on the results of preclinical and clinical studies on the effects of probiotic administration on different types of liver diseases.
Keywords: Hepatic diseases; In vivo and in vitro studies; Liver diseases; Probiotics.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics Approval and Consent to Participate: Not applicable. Consent for Publication: Not applicable. Competing Interests: The authors declare no competing interests.
Similar articles
-
Probiotics and Liver Disease: Where Are We Now and Where Are We Going?J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S188-S190. doi: 10.1097/MCG.0000000000000712. J Clin Gastroenterol. 2016. PMID: 27741172
-
Gut microbiota and probiotics in chronic liver diseases.Dig Liver Dis. 2011 Jun;43(6):431-8. doi: 10.1016/j.dld.2010.10.015. Epub 2010 Dec 16. Dig Liver Dis. 2011. PMID: 21163715 Review.
-
[Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].Ter Arkh. 2017;89(8):120-128. doi: 10.17116/terarkh2017898120-128. Ter Arkh. 2017. PMID: 28914862 Review. Russian.
-
Gut microbiota and liver diseases.World J Gastroenterol. 2015 Feb 14;21(6):1691-702. doi: 10.3748/wjg.v21.i6.1691. World J Gastroenterol. 2015. PMID: 25684933 Free PMC article. Review.
-
Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases.Front Cell Infect Microbiol. 2022 Apr 4;12:774335. doi: 10.3389/fcimb.2022.774335. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35444959 Free PMC article. Review.
Cited by
-
Gut microbiome alterations and hepatic encephalopathy post-TIPS in liver cirrhosis patients.J Transl Med. 2025 Jul 4;23(1):745. doi: 10.1186/s12967-025-06774-y. J Transl Med. 2025. PMID: 40615853 Free PMC article.
References
-
- Mokdad AA et al (2014) Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 12:1–24 - DOI
-
- World Health Organization, Department of Mental Health, Substance Abuse (2004) Global status report on alcohol 2004. World Health Organization
-
- Zhou B et al (2016) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4· 4 million participants. Lancet 387(10027):1513–1530 - DOI
-
- Abarca-Gómez L et al (2017) Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128· 9 million children, adolescents, and adults. Lancet 390(10113):2627–2642 - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical